'Forced into a virtual world': How pharma R&D bounced back from a once-in-a-lifetime pandemic With the pricing situation 'untenable' in Europe, Bluebird will wind down its operations in the 'broken' market GE Healthcare moves imaging, clinical analytics platforms to Amazon Web Services cloud CMS proposes pulling model that ties Part B drug prices to those paid overseas BioNTech, eyeing $18B+ in COVID-19 vaccine sales this year, poised to join the ranks of the world's top drugmakers Insurers came back down to Earth in Q2 following sky-high profits a year ago Epizyme CEO Bazemore passes the baton as company looks to 'next phase of growth' COVID-19 vaccines, safety policies offer strong rallying cries for labor campaigns Biohaven's Nurtec ODT outmuscles AbbVie's Ubrelvy in gaining new migraine patients following key FDA nod COVID-19 tracker: Pentagon to mandate vaccines; Gilead requires jabs for U.S. employees Featured Story | By Annalee Armstrong Clinical trials are the lifeblood of any drug company. Without clinical research, new treatments do not get approved or sold. But what happens when a once-in-a-hundred year pandemic sends the world into lockdown? read more |
| |
|---|
|
Top Stories By Kevin Dunleavy Bluebird Bio will concentrate its efforts in the United States, winding down its operations in Europe because the company couldn't agree on pricing for its costly, one-time gene therapies. read more By Andrea Park GE Healthcare will begin moving several of its software platforms to the AWS cloud, making it easier for healthcare providers and artificial intelligence developers alike to access clinical data to improve patient care. read more By Robert King CMS decided to pull a controversial model that ties prices for certain Part B drugs to those paid overseas after a series of legal defeats. read more By Fraiser Kansteiner Now prophesizing €15.9 billion ($18.7 billion) in COVID-19 vaccine sales this year, mRNA specialist BioNTech will likely join the ranks of the world’s top 20 drugmakers by revenue this year. It’s a similar story to Moderna, which has vaccine orders for 2021 worth some $20 billion. read more By Paige Minemyer Payers are bracing for the pandemic's influence to continue through the end of this year. read more By Amirah Al Idrus With two approvals for its cancer drug Tazverik and trials in various other tumor types underway, Epizyme is making changes at the top. CEO Robert Bazemore is handing the reins to Grant Bogle, a biopharma veteran who’s been on the company’s board since 2019. read more By Dave Muoio As healthcare workers' unions seek to balance personal safety against rights protections, their positions stand to impact recruitment efforts and contract negotiations extending well beyond the pandemic. read more By Noah Higgins-Dunn Biohaven's oral CGRP med now tops AbbVie’s version when it comes to new-to-brand prescriptions, an impressive feat for a specialized drugmaker facing off against one of pharma's largest players. read more By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner The Pentagon said U.S. Military members will soon be required to get vaccinated against COVID-19, a move supported by President Joe Biden. Meanwhile, Gilead Sciences said it will require its U.S. employees and contractors to get the vaccine by the beginning of October. Plus more headlines. read more |
